We next evaluated the functional significance of immune modulator therapy by examining its impact on anti-tumor activity of MM-specific CTL generated with HLA-A2 XBP1/CD138/CS1 peptides including heteroclitic XBP1 US184-192 (YISPWILAV), heteroclitic XBP1 SP367-375 (YLFPQLISV), native CD138260-268 (GLVGLIFAV), and native CS1239-247 (SLFVLGLFL), as described previously [14–17]. This evidence concerns the gene SDC1 and neoplasm.